US2019328708A1PendingUtilityA1

Method for administration

Assignee: HOFFMANN LA ROCHEPriority: Mar 19, 2012Filed: Jul 12, 2019Published: Oct 31, 2019
Est. expiryMar 19, 2032(~5.6 yrs left)· nominal 20-yr term from priority
A61P 35/00A61K 9/146A61K 31/40A61K 31/401A61K 2121/00
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A method of treating a patient suffering from cancer, comprising administering to said patient a pharmaceutical composition containing as an active ingredient Compound A in an amount from about 800 mg/day to about 3000 mg/day, daily, for up to about 7 days, followed by a rest period of up to about 21 days, said administration starting on the first day of a 28 day treatment cycle. 
     
     
         2 . A method of treating a patient suffering from cancer, comprising administering to said patient a pharmaceutical composition containing as an active ingredient Compound A in an amount from about 800 mg/day to about 3000 mg/day, daily, for up to about 5 days, followed by a rest period of up to about 23 days, said administration starting on the first day of a 28 day treatment cycle. 
     
     
         3 . The method of  claim 2  wherein Compound A is administered in an amount from about 1000 mg/day to about 2500 mg/day. 
     
     
         4 . The method of  claim 3  wherein Compound A is administered in an amount of from about 1250 mg/day to about 1800 mg/day. 
     
     
         5 . The method of  claim 1  wherein the treatment cycle being repeated every 28 days for up to about 12 cycles. 
     
     
         6 . The method of  claim 1  wherein Compound A is administered twice daily in equal doses. 
     
     
         7 . The method of  claim 1  wherein the cancer is colorectal cancer. 
     
     
         8 . The method of  claim 1  wherein the cancer is prostate cancer. 
     
     
         9 . The method of  claim 1  wherein the cancer is lung cancer. 
     
     
         10 . The method of  claim 1  wherein the cancer is kidney cancer. 
     
     
         11 . The method of  claim 1  wherein the cancer is breast cancer.

Join the waitlist — get patent alerts

Track US2019328708A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.